ROIV
Roivant Sciences Ltd.
Latest Form 4:Sale$6.4MbySukhatme Mayukh (President & CIO) · filed Aug 22, 2026
Roivant Sciences Ltd. (ROIV) has 87 SEC Form 4 filings (244 transaction rows) in the rolling window, disclosed by 12 distinct insiders. Most recent filing: Aug 25, 2026.
The most active filer is President & Immunovant CEO Venker Eric with 22 filings. Insiders have net sold $269.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Matthew Gline
- Employees:721
- HQ:London, GL, GB
- IPO:2020-12-08
Insider Buying
$50K
reported purchases (SEC code P)
Insider Selling
$936.6M
reported sales (SEC code S)
Unique Insiders
12
in the rolling window
Market Cap
$25.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| President & CIO | Sale | 172,899 | $6.4M | Aug 22 | SEC ↗ | |
| President & CIO | Sale | 17,519 | $653K | Aug 22 | SEC ↗ | |
| President & CIO | Sale | 144,756 | $5.3M | Aug 22 | SEC ↗ | |
| President & CIO | Sale | 243,177 | $8.8M | Aug 19 | SEC ↗ | |
| President & CIO | Sale | 284,707 | $10.3M | Aug 19 | SEC ↗ | |
| President & CIO | Sale | 136,942 | $5.0M | Aug 19 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $7.0M | Jul 30 | SEC ↗ | |
Fitzgerald MeghanFirst in 3 months | Director | Sale | 10,000 | $349K | Jul 2 | SEC ↗ |
Epperly Melissa B,First in 4 months | Director | Sale | 17,750 | $610K | Jul 1 | SEC ↗ |
MANCHESTER KEITH SFirst in 5 months | Director | Sale | 625,783 | $21.3M | Jul 1 | SEC ↗ |
MANCHESTER KEITH SFirst in 5 months | Director | Sale | 800,000 | $27.6M | Jul 1 | SEC ↗ |
MANCHESTER KEITH SFirst in 5 months | Director | Sale | 212,380 | $7.5M | Jul 1 | SEC ↗ |
Gold Daniel AllenFirst in 5 months | Director | Sale | 625,783 | $21.3M | Jul 1 | SEC ↗ |
Gold Daniel AllenFirst in 5 months | Director | Sale | 800,000 | $27.6M | Jul 1 | SEC ↗ |
Gold Daniel AllenFirst in 5 months | Director | Sale | 12,380 | $437K | Jul 1 | SEC ↗ |
QVT Financial LPFirst in 5 months | Director by Deputization | Sale | 625,783 | $21.3M | Jun 30 | SEC ↗ |
QVT Financial LPFirst in 5 months | Director by Deputization | Sale | 800,000 | $27.6M | Jun 30 | SEC ↗ |
QVT Financial LPFirst in 5 months | Director by Deputization | Sale | 12,380 | $437K | Jun 30 | SEC ↗ |
Sukhatme MayukhFirst in 5 months | President & CIO | Sale | 500,000 | $17.1M | Jun 29 | SEC ↗ |
Sukhatme MayukhFirst in 5 months | President & CIO | Sale | 500,000 | $17.0M | Jun 29 | SEC ↗ |
| President & Immunovant CEO | Sale | 200,000 | $6.6M | Jun 26 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $6.1M | May 22 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $5.9M | Apr 22 | SEC ↗ | |
Gline MatthewFirst in 4 months | CEO | Sale | 289,774 | $8.4M | Apr 20 | SEC ↗ |
Humes JenniferFirst filing | Chief Accounting Officer | Sale | 13,538 | $384K | Apr 10 | SEC ↗ |
Fitzgerald MeghanFirst filing | Director | Sale | 70,000 | $1.9M | Mar 30 | SEC ↗ |
| President & Immunovant CEO | Sale | 200,000 | $5.6M | Mar 19 | SEC ↗ | |
Epperly Melissa B,First filing | Director | Sale | 41,861 | $1.2M | Mar 18 | SEC ↗ |
Torti FrankFirst filing | President and Vant Chair | Sale | 1,400,000 | $38.4M | Feb 23 | SEC ↗ |
Torti FrankFirst filing | President and Vant Chair | Sale | 1,012,610 | $27.5M | Feb 23 | SEC ↗ |
Torti FrankFirst filing | President and Vant Chair | Sale | 587,390 | $16.2M | Feb 23 | SEC ↗ |
| President & Immunovant CEO | Sale | 200,000 | $5.3M | Feb 18 | SEC ↗ | |
| Director | Sale | 425,000 | $11.3M | Feb 13 | SEC ↗ | |
| Director | Sale | 425,000 | $11.4M | Feb 13 | SEC ↗ | |
| Director | Sale | 375,784 | $10.0M | Feb 13 | SEC ↗ | |
| Director | Sale | 425,000 | $11.3M | Feb 13 | SEC ↗ | |
| Director | Sale | 425,000 | $11.4M | Feb 13 | SEC ↗ | |
| Director | Sale | 375,784 | $10.0M | Feb 13 | SEC ↗ | |
| Director by Deputization | Sale | 425,000 | $11.3M | Feb 13 | SEC ↗ | |
| Director by Deputization | Sale | 425,000 | $11.4M | Feb 13 | SEC ↗ | |
| Director by Deputization | Sale | 375,784 | $10.0M | Feb 13 | SEC ↗ | |
| President & CIO | Sale | 339,441 | $9.0M | Feb 11 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $4.4M | Jan 14 | SEC ↗ | |
| President & CIO | Sale | 311,873 | $6.8M | Dec 31 | SEC ↗ | |
| President & CIO | Sale | 1,018,995 | $22.1M | Dec 31 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $4.5M | Dec 29 | SEC ↗ | |
| President & Immunovant CEO | Sale | 75,000 | $1.7M | Dec 29 | SEC ↗ | |
Pulik RichardFirst filing | CFO | Sale | 406,731 | $9.1M | Dec 29 | SEC ↗ |
Sukhatme MayukhFirst filing | President & CIO | Sale | 26,831 | $620K | Dec 19 | SEC ↗ |
| Director | Sale | 917,282 | $21.1M | Dec 18 | SEC ↗ | |
| Director | Sale | 777,332 | $17.9M | Dec 18 | SEC ↗ | |
| Director | Sale | 917,282 | $21.1M | Dec 18 | SEC ↗ | |
| Director | Sale | 777,332 | $17.9M | Dec 18 | SEC ↗ | |
| Director by Deputization | Sale | 917,282 | $21.1M | Dec 18 | SEC ↗ | |
| Director by Deputization | Sale | 777,332 | $17.9M | Dec 18 | SEC ↗ | |
Gline MatthewFirst in 3 months | CEO | Sale | 1,740,000 | $37.7M | Dec 17 | SEC ↗ |
| 10% Owner | Sale | 774,142 | $16.8M | Dec 15 | SEC ↗ | |
| 10% Owner | Sale | 1,975,858 | $43.4M | Dec 15 | SEC ↗ | |
| 10% Owner | Sale | 353,745 | $7.8M | Dec 15 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $4.2M | Dec 11 | SEC ↗ | |
MANCHESTER KEITH SFirst filing | Director | Sale | 1,300,000 | $26.3M | Nov 21 | SEC ↗ |
QVT Financial LPFirst filing | Director by Deputization | Sale | 1,300,000 | $26.3M | Nov 21 | SEC ↗ |
Gold Daniel AllenFirst filing | Director | Sale | 1,300,000 | $26.3M | Nov 21 | SEC ↗ |
| 10% Owner | Sale | 287,283 | $6.0M | Nov 17 | SEC ↗ | |
| 10% Owner | Sale | 1,027,670 | $20.9M | Nov 17 | SEC ↗ | |
| 10% Owner | Sale | 539,650 | $11.1M | Nov 17 | SEC ↗ | |
| President & Immunovant CEO | Sale | 200,000 | $4.0M | Nov 7 | SEC ↗ | |
| President & Immunovant CEO | Sale | 414,683 | $7.0M | Oct 17 | SEC ↗ | |
| President & Immunovant CEO | Sale | 318,282 | $5.4M | Oct 17 | SEC ↗ | |
| President & Immunovant CEO | Sale | 118,418 | $2.0M | Oct 17 | SEC ↗ | |
| President & Immunovant CEO | Sale | 104,940 | $1.7M | Oct 14 | SEC ↗ | |
| President & Immunovant CEO | Sale | 20,727 | $337K | Oct 14 | SEC ↗ | |
| President & Immunovant CEO | Sale | 171,396 | $2.8M | Oct 8 | SEC ↗ | |
| President & Immunovant CEO | Sale | 355,161 | $5.7M | Oct 8 | SEC ↗ | |
| President & Immunovant CEO | Sale | 138,602 | $2.2M | Oct 8 | SEC ↗ | |
Venker EricFirst filing | President & Immunovant CEO | Sale | 683,818 | $10.2M | Sep 23 | SEC ↗ |
Venker EricFirst filing | President & Immunovant CEO | Sale | 416,182 | $6.2M | Sep 23 | SEC ↗ |
Venker EricFirst filing | President & Immunovant CEO | Sale | 611,000 | $9.1M | Sep 23 | SEC ↗ |
Gline MatthewFirst filing | CEO | Purchase | 3,315 | $50K | Sep 18 | SEC ↗ |
Ramaswamy VivekFirst filing | 10% Owner | Sale | 1,195,000 | $14.9M | Sep 5 | SEC ↗ |
Ramaswamy VivekFirst filing | 10% Owner | Sale | 194,933 | $2.5M | Sep 5 | SEC ↗ |
Ramaswamy VivekFirst filing | 10% Owner | Sale | 385,816 | $5.0M | Sep 5 | SEC ↗ |
Related companies
Roivant Sciences Ltd. is in the Healthcare sector.